Brief: Evolus Announces Successful Completion Of Phase 2 Study Evaluating “Extra-Strength” Dose Of Jeuveau
22/06/2023 13:53
June 22 (Reuters) - Evolus Inc EOLS.O :
* EVOLUS ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 2 STUDY
EVALUATING “EXTRA-STRENGTH” DOSE OF JEUVEAU ®
* EVOLUS INC - PRESENTATION OF FULL DATASET FROM
"EXTRA-STRENGTH"
GLABELLAR LINE STUDY WILL BE PLANNED FOR A MEDICAL MEETING IN Q4
2023
Source text for Eikon: ID:nBw7yHf5La
Further company coverage: EOLS.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Evolus
See all newsEvolus Inc reports results for the quarter ended June 30 - Earnings Summary
Evolus Q2 revenue rises 21%, lifts 2026 outlook
Brief: Evolus Q2 Product Revenue USD 83.35 Million
Evolus Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe